Articles tagged with Breast Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A randomized clinical trial of 3,020 patients with high-risk nonmetastatic breast cancer found daily aspirin therapy had no effect on breast cancer recurrence or survival in early follow-up. Aspirin should not be recommended as an adjuvant breast cancer treatment despite its potential benefits and wide availability
A large-scale study of 572 Asian families with BRCA1 and BRCA2 mutations found increased breast cancer risk over time, with highest incidence at age 55. The study provides a new framework for estimating cancer risks in Asian carriers, supporting tailored clinical management approaches.
A study published in the Canadian Association of Radiologists Journal shows an increase in breast cancer diagnoses among females in their Twenties, Thirties, and Forties. Younger women are more likely to be diagnosed at later stages and with more aggressive cancer.
The ECOG-ACRIN Cancer Research Group will present late-breaking findings on prostate cancer, breast cancer, and pancreas cancer at ASCO 2024. These studies include optimal chemotherapy for Black women with breast cancer and results from the first randomized national trial in older adults with pancreas cancer.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
Research shows breast cancer survivors are at increased risk of developing second cancers, including endometrial and ovarian cancer for women, and prostate cancer for men. Socioeconomic deprivation is linked to a greater risk of second cancers among breast cancer survivors.
Women with germline BRCA pathogenic variants face increased risk of mortality from postpartum breast cancer, particularly those diagnosed under 10 years after giving birth. The study highlights the importance of genetic counseling and tailored prevention strategies for these high-risk individuals.
The innovative Integrated Virtual Care (IVC) program successfully connected residents with family physicians in Renfrew County, addressing the rural shortage of primary care providers. Over 2,800 unique patient appointments were conducted, with 70% done virtually, offering comprehensive team-based primary care.
A national cohort study found that neighborhood disadvantage was independently associated with shorter breast cancer–specific survival. The study suggests potential unaccounted-for mechanisms, including both nonbiologic and biologic factors, and highlights the need for further research.
Researchers at the University of Toronto have discovered a DNA repair mechanism that uses nuclear metamorphosis to fix double-strand breaks in human cells. This discovery has significant implications for cancer treatment and premature aging, and may lead to new therapeutic avenues.
A new study published in JNCI Cancer Spectrum found that following a healthy diet, such as the DASH diet, lowers the risk of cardiovascular disease in breast cancer survivors. Women whose diets were most similar to DASH had a 47% lower risk of heart failure and other cardiovascular-related events.
A study by the University of Gothenburg found that women with triple-negative breast cancer and high immune cell levels have a lower relapse risk after surgery. This suggests that these patients may not need chemotherapy, despite having faster-growing tumors and higher relapse rates than other breast cancers.
The new Lancet Commission on Breast Cancer warns that people with metastatic breast cancer have been often forgotten, highlighting key barriers and inequities in healthcare. The report advocates for six crucial areas for change, including improving early diagnosis programs and communication with patients.
Researchers at Insilico Medicine have identified a new class of Polθ inhibitors featuring central scaffolding rings, designed using Chemistry42, with significant enzymatic and cellular potency. The discovery showcases the potential of AI in medicinal chemistry for precise molecular modifications.
A new Lancet Commission reveals that many people with breast cancer are being systematically left behind due to inaction on inequities and hidden suffering. The commission highlights the need for better patient support, including improved communication between patients and healthcare professionals.
Researchers have discovered how softer tumor environments prime cancer cells to better survive metastasis. The study found that soft environments alter the cancer cells' preference for 'fuel', equipping them with a more resilient energy pathway.
Young breast cancer survivors without germline pathogenic variants are at lower risk for developing a second primary breast cancer within the first decade after diagnosis. This study informs treatment decision-making and follow-up care considerations in this population.
Researchers developed an AI algorithm to identify normal mammograms and ran a simulation on patient data, revealing that AI can reduce unnecessary testing while maintaining cancer detection rates. The study suggests that AI can help doctors focus on more questionable scans, reducing false positives and improving workflows.
A new study found that survival rates after hip or spine fractures are comparable to or worse than those seen in patients with certain types of cancer. The study, which analyzed data from over 100,000 Canadians aged 65 and older, highlights the urgent need for secondary prevention interventions before hospital discharge.
Saruparib, a selective PARP1 inhibitor, demonstrates clinical benefit in patients with HRR-deficient breast cancers. The objective response rate was 48.4%, and progression-free survival was 9.1 months. The drug's favorable safety profile enables patients to stay on treatment for longer durations.
A Phase I/II trial led by the University of Texas M. D. Anderson Cancer Center found saruparib effective against HRR-deficient breast cancers, demonstrating a favorable safety profile and high response rate. The drug's low dose-reduction rate compared to approved PARP inhibitors may enable longer treatment duration.
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
Cold Spring Harbor Laboratory researchers developed Accelerated SuFEx Click Chemistry to create over 150 new molecular compounds, including derivatives of complex natural molecules. These compounds show promise as leads for developing antibiotics and cancer therapies.
A large trial enrolling nearly 2,800 patients from five countries has clarified the situation for patients with larger metastases. The study found that leaving most of the lymph nodes intact resulted in similar recurrence rates as completion axillary dissection, but with fewer arm-related complications.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Research highlights socioecologic factors contributing to racial disparities in breast cancer prognostic scores, emphasizing the impact of structural racism on health outcomes. Additional research is needed to better understand the influence of social determinants on breast cancer biology among disadvantaged communities.
Researchers from the University of Southern Denmark have identified specific groups of cells driving resistance to chemotherapy in TNBC, offering new biomarkers and alternative treatment options. The studies shed light on the mechanisms behind chemoresistance and its epigenetic control.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
A new study suggests that early-stage triple-negative breast cancer (TNBC) patients with high levels of immune cells in their tumors may have a lower risk of recurrence and better survival rates even without chemotherapy. Higher TILs in breast cancer tissue were associated with lower recurrence rates among participants.
A study published in Nature Genetics reveals early cell changes in healthy carriers of BRCA1 and BRCA2 gene mutations, suggesting a potential target for breast cancer prevention. The researchers created the world's largest catalogue of human breast cells, which may lead to the use of existing immunotherapy drugs as an early intervention.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
A team of researchers from Hiroshima University has discovered a molecule called AIbZIP that promotes the production of cancer cells in triple-negative breast cancer. This finding may lead to new therapeutic targets for the treatment of this aggressive form of breast cancer.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
Scientists from UC3M and Johns Hopkins University have developed a computational model that simulates the invasion process of cancer cells based on the characteristics of surrounding tissue and cell junctions. The model allows for predicting tumor evolution in patients by analyzing mechanical properties of the microenvironment.
A combined PET-MRI scan improved treatment outcomes for 57 out of 205 patients with early-stage breast cancer. The scan helped doctors spot signs of tumour spread, enabling alternative treatments such as chemotherapy or different surgical approaches.
A new AI tool can predict which breast cancer patients are at risk of chronic arm swelling after surgery and radiotherapy. The tool, developed by international researchers, uses machine learning algorithms to analyze patient data and provides easily understandable explanations for doctors and patients.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
Researchers found that young breast cancer patients who received a low-dose radiotherapy boost had a lower risk of local recurrence after 10 years, with only 4.4% experiencing recurrence. In contrast, high-dose boosts resulted in fewer recurrences but also more severe fibrosis and cosmetic issues.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
Researchers have developed a new AI model, AsymMirai, to predict 5-year breast cancer risk from mammograms. The model performs almost as well as the state-of-the-art Mirai, but with an interpretable reasoning process, making it a valuable adjunct to human radiologists.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
A clinical trial found that breast tomosynthesis reduces interval breast cancer by 49%, making it a valuable tool for early detection. The test also detects smaller tumors and improves prognosis.
A randomized controlled trial found that exercise programmes reduced fatigue and improved quality of life for patients with metastatic breast cancer. The study showed the greatest benefit among younger patients, but also suggested that supervised exercise can be beneficial for all patients with advanced disease.
A new review by UMass Amherst researchers highlights the need for more research on breast cancer cell dormancy, which is a contributing factor to metastatic breast cancer. The study aims to identify gaps in research and develop better models to understand and treat this phenomenon.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
The study found a significant decrease in newly diagnosed breast cancer cases, with the largest declines seen among women aged 50-69 and Hispanic women. The results have implications for how physicians and policymakers address issues related to diagnostic delays during the pandemic.
Researchers developed a GPS nanoparticle platform that can home in on cancer cells to deliver gene-editing tools, targeting the protein implicated in tumor growth and spread. The technique may offer a more precise and effective treatment for notoriously hard-to-treat basal-like breast cancers.
A study found that up to 87% of childhood cancer survivors are not following recommended screening guidelines, leaving them vulnerable to late effects such as heart disease and certain cancers. The lack of awareness and barriers to adherence may contribute to this low rate, highlighting the need for improved support and education.
Researchers at the University of Cincinnati Cancer Center have identified a new protein called p47 that helps prevent breast cancer metastasis. The study found that lower p47 expression was correlated with higher breast cancer metastasis, and that increasing p47 function could potentially lead to new therapies.
Researchers have designed a candidate drug to target the K-Ras G12D mutation, responsible for nearly half of all pancreatic cancer cases. The molecule permanently modifies the mutation, stopping tumor growth in cancer cell lines and animal models.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
A study from Florida Atlantic University identifies key social factors contributing to low breast cancer screening rates in the US. Socioeconomic status, access to healthcare, and insurance status are among the top influencers of breast cancer screening behavior.
Researchers deciphered the male breast cancer genome, identifying gene mutations and molecular profiles that could impact diagnosis and treatment. The study found mutations in genes known to drive cancer growth and structural variants impacting other cancer-associated genes.
The NCI-MATCH precision medicine trial discovered that trastuzumab-pertuzumab, approved for HER2-positive breast cancer, can shrink tumors in patients with other types of cancer and high levels of the HER2 gene. The study found a 12% confirmed overall response rate, with partial responses in various cancers.
A study published in JAMA Oncology found that MRI monitoring in women with BRCA1 mutations significantly reduces breast cancer mortality without the need for preventive mastectomy. The research included data from 2,488 women and showed a notable decrease in mortality rate among participants.
Researchers identified a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment.
A new study published in Radiology found that annual breast cancer screening beginning at age 40 and continuing until 79 results in the highest mortality reduction. The study analyzed Cancer Intervention and Surveillance Modeling Network (CISNET) estimates and showed that annual screening reduces breast cancer deaths by 41.7%.
Researchers at Tohoku University have developed a novel monoclonal antibody targeting HER2-positive breast cancer cells, providing a new tool for treating this aggressive subtype. The antibody disrupts cell growth and proliferation while minimizing harm to surrounding healthy tissue.
A study co-led by Prof. Kelly Metcalfe finds risk-reducing mastectomies significantly reduce breast cancer risk and death probability in women with a BRCA1 or BRCA2 genetic variant. The procedure reduces the risk of breast cancer by 80% and decreases mortality to less than 1%.